摘要
目的:对滑膜炎颗粒治疗膝关节骨关节炎(KOA)的随机对照试验(RCT)进行Meta分析,旨在评估滑膜炎颗粒治疗KOA的有效性和安全性。方法:全面检索8个主要中英文数据库,收集滑膜炎颗粒治疗KOA的RCT。使用Cochrane偏倚风险评估工具对纳入研究的质量进行评定,利用RevMan 5.3软件进行统计分析,计数变量采用比值比(odds ratio,OR)为效应量,计量变量采用加权均数差为效应量(WMD,Weight Mean Difference),各效应量均提供其95%CI。结果:纳入的7个RCT研究质量偏低。Meta分析结果显示,滑膜炎颗粒组治疗有效率高于安慰剂组,滑膜炎颗粒联合玻璃酸钠关节腔注射及塞来昔布胶囊口服的VAS评分变化大于单纯玻璃酸钠关节腔注射联合塞来昔布胶囊口服。与酮基布洛芬相比,滑膜炎颗粒组不良反应率低,与安慰剂相比较滑膜炎颗粒并没有增加不良反应的发生。结论:滑膜炎颗粒治疗KOA有效,未增加不良反应的发生。受纳入研究数量和质量限制,需要开展大样本的真实世界研究以获取更高质量的证据。
Objective:This study aimed to evaluate the efficacy and safety of Huamoyan granules in the treatment of Knee Osteoarthritis(KOA)by systematic review and meta-analysis.Methods:A comprehensive searching in 8 databases was conducted to collect Randomized Controlled Trial(RCT)of Huamoyan granules for treatment of KOA.The Cochrane bias risk assessment tool was used to assess the quality of the included studies.RevMan 5.3 software was used to statistical analysis.Results:A total of seven RCTs were included,and the quality of included study was low.Meta-analysis showed that the effective rate of patients in the Huamoyan granule group was higher than the placebo group,and the changes of VAS score of Huamoyan granule combined with sodium hyaluronate injection and celecoxib capsule oral administration were greater than that of sodium hyaluronate injection combined with celecoxib capsule oral administration.Compared with ceftobiprole,the rate of adverse reactions was lower in the Huamoyan granule group,and there was no increase in the incidence of adverse reactions in the Huamoyan granule group compared with placebo.Conclusion:In the treatment of KOA,Huamoyan granules is efficacy and lower incidence of adverse reactions.Because the low quality of the included RCTs,multi-center and large-sample real word study are needed to obtain more scientific and rigorous evidences.
作者
刘明
施树珍
高亚
杨珂璐
邵德成
关健
田金徽
LIU Ming;SHI Shu-zhen;GAO Ya;YANG Ke-lu;SHAO De-cheng;GUAN Jian;TIAN Jin-hui(Evidence-Based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Gansu Lanzhou 730000,China;Evidence-Based Nursing Center,School of Nursing,Lanzhou University,Gansu Lanzhou 730000,China;The Third Hospital of Hebei Medical University,Hebei Shijiazhuang 053000,China;The Third Hospital of Shijiazhuang,Hebei Shijiazhuang 053000,China)
出处
《中国药物评价》
2020年第6期468-473,共6页
Chinese Journal of Drug Evaluation
基金
甘肃省循证医学与临床转化重点实验室开放基金(编号:20170203)。
